Aripiprazole
Product Images NDC 70934-662

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70934-662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (70934 662 30 Master Bottle Label Approval Rev A 04 20)

Label (70934 662 30 Master Bottle Label Approval Rev A 04 20)
This is a description of a medicine called Aripiprazole Tablets, USP 5mg. The package contains 30 tablets and has an NDC number of 70934-662-30. The medicine is a prescription drug and can only be obtained through a doctor. There is also some information about the manufacturer of the medicine.*
FDA Label Image

Figure 1 (Aripiprazole Figure 1)

Figure 1 (Aripiprazole Figure 1)
This appears to be a table or chart showing the effect of various drugs on the pharmacokinetics of aripiprazole. The drugs are categorized as CYP3A inhibitors, CYP2D6 inhibitors, gastric acid blockers, and others. The table shows the percent change and confidence interval in the PK (pharmacokinetics) of aripiprazole when taken with each specific drug compared to when taken alone. It appears to be a reference for healthcare professionals to understand potential drug interactions with aripiprazole.*
FDA Label Image

Figure 2 (Aripiprazole Figure 2)

Figure 2 (Aripiprazole Figure 2)
This appears to be a table or graph showing the effects of various drugs on aripiprazole. The drugs listed include gastric acid blockers, valproate, and ocazapm. The table shows a percentage change relative to a reference without interacting drugs. More specific information on the purpose and results of this study cannot be determined from this text alone.*
FDA Label Image

Figure 3 (Aripiprazole Figure 3)

Figure 3 (Aripiprazole Figure 3)
FDA Label Image

Figure 4 (Aripiprazole Figure 4)

Figure 4 (Aripiprazole Figure 4)
This appears to be a chart or table related to special populations in a study or experiment. The text includes information regarding gender, hepatic impairment, and renal impairment. There is also data related to "Aviiprazcie Fod Change" which is unclear without additional context. However, without further information, it is not possible to provide a more detailed description or interpretation.*
FDA Label Image

Figure 5 (Aripiprazole Figure 5)

Figure 5 (Aripiprazole Figure 5)
FDA Label Image

Figure-6 (Aripiprazole Figure 6)

Figure-6 (Aripiprazole Figure 6)
FDA Label Image

Figure-7 (Aripiprazole Figure 7)

Figure-7 (Aripiprazole Figure 7)
FDA Label Image

Figure-8 (Aripiprazole Figure 8)

Figure-8 (Aripiprazole Figure 8)
The given text seems to be a table presenting the number of subjects at risk and the proportion with relapse with regards to the medication named "ARFPRAZOLE". It appears that the table has columns for different time periods and corresponding values. It may be related to a clinical trial or study.*
FDA Label Image

Aripiprazole Chemical Structure (Aripiprazole Structure)

Aripiprazole Chemical Structure (Aripiprazole Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.